Rankings
▼
Calendar
UTHR Q1 2023 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena
UTHR
United Therapeutics Corporation
$24B
Q1 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$507M
+9.7% YoY
Gross Profit
$455M
89.7% margin
Operating Income
$284M
56.1% margin
Net Income
$241M
47.5% margin
EPS (Diluted)
$4.86
QoQ Revenue Growth
+3.1%
Cash Flow
Operating Cash Flow
$375M
Free Cash Flow
$334M
Stock-Based Comp.
-$12M
Balance Sheet
Total Assets
$6.3B
Total Liabilities
$1.2B
Stockholders' Equity
$5.1B
Cash & Equivalents
$1.2B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$507M
$462M
+9.7%
Gross Profit
$455M
$436M
+4.3%
Operating Income
$284M
$288M
-1.3%
Net Income
$241M
$240M
+0.4%
Revenue Segments
Tyvaso
$238M
47%
Remodulin
$121M
24%
Orenitram
$88M
17%
Unituxin
$49M
10%
Adcirca
$7M
1%
Product and Service, Other
$3M
0%
Geographic Segments
UNITED STATES
$470M
93%
Non-US
$37M
7%
← FY 2023
All Quarters
Q2 2023 →